Genovis AB (publ.) (STO:GENO)
Sweden · Delayed Price · Currency is SEK 16.90
-0.40 (-2.31%)
Mar 2, 2026, 5:24 PM CET
Genovis AB (publ.) Revenue
In the year 2025, Genovis AB (publ.) had annual revenue of 129.65M SEK, down -1.27%. Genovis AB (publ.) had revenue of 40.26M in the quarter ending December 31, 2025, with 39.30% growth.
Revenue
129.65M
Revenue Growth
-1.27%
P/S Ratio
8.61
Revenue / Employee
3.60M
Employees
36
Market Cap
1.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 129.65M | -1.67M | -1.27% |
| Dec 31, 2024 | 131.32M | -27.75M | -17.44% |
| Dec 31, 2023 | 159.07M | 55.51M | 53.60% |
| Dec 31, 2022 | 103.56M | 9.89M | 10.55% |
| Dec 31, 2021 | 93.68M | 32.65M | 53.49% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Saniona AB | 434.40M |
| Cantargia AB | 316.70M |
| BioInvent International AB | 226.50M |
| Oncopeptides AB | 71.12M |
| Egetis Therapeutics AB | 62.40M |
| Medivir AB | 8.50M |
| Xspray Pharma AB | 6.43M |
| Diamyd Medical AB | 349.00K |
Genovis AB (publ.) News
- 1 year ago - Genovis AB (OSTO:GENO) Q3 2024 Earnings Report Preview: What to Expect - GuruFocus